导管持续心包引流加白介素-2治疗恶性心包积液  

Treatment of malignant pericardial effusion caused by pulmonary malignant tumor with catheter drainage of pericardium and intracavitary administration of interleukin Ⅱ.

作　　者：夏淮玲[1] 操乐杰[1] 高圣堂[1] 

机构地区：[1]安徽省立医院呼吸科,230001

出　　处：《临床肺科杂志》2007年第1期52-53,共2页Journal of Clinical Pulmonary Medicine

基　　金：安徽省科技厅重点科研课题基金资助(项目编号01023024)

摘　　要：目的 观察导管持续心包引流并白介素-2心包腔内注射对恶性心包积液的疗效。方法5例恶性肿瘤转移引起的恶性心包积液行中心静脉导管持续引流后，心包腔内注射白细胞介素-2 100-200万U。结果 5例中，4便心包积液完全缓解，1例部分缓解；除1例失去随访，4例心包积液未再生长。最长达11个月，结论 治疗恶性心包积液安全、有效、副作用少。Objective To observe therapeutic effect of catheter drainage of pericardium and intracavitary administration of interleukin Ⅱ in malignant pericardium effusion caused by pulmonary malignant tumor. Methods Five patients with malignant pericardial effusion caused by pulmonary malignant tumor received the treatment of continuing drainage of pericardium with the central vein catheter and intracavitary administration of interleukin Ⅱ. The dosage given was interleukin Ⅱ between 10 × 10^7 -20 × 10^7 units every time. Results There were 4 patients achieved complete remission, and 1 achieved partial remission. Except one case, all other cases were followed up, and found that the malignant pericardium effusion was controlled completely, in one case lasting to 11 months. Conclusion The treatment of continuing drainage of pericardium with the central vein catheter and intracavitary administration of interleukin Ⅱ is a good method for malignant pericardial effusion. It is also safe with less adverse reaction. It is thus worthy of being recommended for a wide use in clinic application.

关 键 词：导管持续心包引流 恶性心包积液 治疗 

分 类 号：R730.5[医药卫生—肿瘤]